Association of simvastatin and hyperlipidemia with periodontal status and bone metabolism markers.

Abstract

BACKGROUND:

The objective of this study is to determine whether simvastatin consumption and hyperlipidemia are associated with a worse periodontal condition and specific bone activity biomarkers.

METHODS:

This cross-sectional and analytic study includes 73 patients divided into three groups: 1) simvastatin-treated patients with hyperlipidemia (n = 29); 2) patients with hyperlipidemia treated by diet alone (n = 28); and 3) normolipidemic patients (controls, n = 16). The periodontal clinical variables of all participants were gathered, a blood sample was drawn from each to determine the lipid profile (total cholesterol, triglycerides, low-density lipoprotein, and high-density lipoprotein), serum levels of acute-phase reactants (C-reactive protein), erythrocyte sedimentation rate, and bone metabolism markers (osteoprotegerin [OPG], osteocalcin, procollagen type I N-terminal propeptide, and C-terminal telopeptide of type I collagen).

RESULTS:

The mean ESR was higher in the diet-treated patients with hyperlipidemia than in the normolipidemic controls (P = 0.04). Serum OPG concentrations were significantly higher in the simvastatin-treated patients with hyperlipidemia than in the diet-treated patients with hyperlipidemia (P = 0.05). Multivariable linear regression analysis adjusted for age, sex, tobacco, and alcohol revealed that, compared with the normolipidemic patients, the simvastatin-treated patients with hyperlipidemia showed a mean reduction of 0.8 mm (95% confidence interval = -1.5 to 0.0, P = 0.05) in clinical attachment loss.

CONCLUSIONS:

Within the limits of this study, the findings suggest that the intake of simvastatin is associated with increasing serum OPG concentrations, and this could have a protective effect against bone breakdown and periodontal attachment loss. The baseline systemic inflammatory state of patients with hyperlipidemia is indicated by their increased erythrocyte sedimentation rate.

• Authors: Antonio Magán-Fernández, Lara Papay-Ramírez, Juan Tomás, Rafael Marfil-Álvarez, Manfredi Rizzo, Manuel Bravo, Francisco Mesa
• Journal: Journal of periodontology (J Periodontol) Vol. 85 Issue 10 Pg. 1408-15 (Oct 2014) ISSN: 1943-3670 [Electronic] United States
• PMID: 24555750 (Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers
• Cholesterol, HDL
• Cholesterol, LDL
• Collagen Type I
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Hypolipidemic Agents
• Osteoprotegerin
• Peptide Fragments
• Peptides
• Procollagen
• Triglycerides
• collagen type I trimeric cross-linked peptide
• procollagen Type I N-terminal peptide
• Osteocalcin
• C-Reactive Protein
• Cholesterol
• Simvastatin

Topics

• Adult
• Aged
• Alcohol Drinking
• Biomarkers (analysis)
• Blood Sedimentation
• C-Reactive Protein (analysis)
• Cholesterol (blood)
• Cholesterol, HDL (blood)
• Cholesterol, LDL (blood)
• Collagen Type I (blood)
• Cross-Sectional Studies
• Female
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Hyperlipidemias (diet therapy, drug therapy)
• Hypolipidemic Agents (therapeutic use)
• Male
• Middle Aged
• Osteocalcin (blood)
• Osteoprotegerin (blood)
• Peptide Fragments (blood)
• Peptides (blood)
• Periodontal Attachment Loss (classification)
• Periodontal Index
• Procollagen (blood)
• Simvastatin (therapeutic use)
• Smoking
• Triglycerides (blood)